SupplementalTables from Mutations in the RAS/MAPK Pathway Drive Replication Repair–Deficient Hypermutated Tumors and Confer Sensitivity to MEK Inhibition

Table S1: Summary of likely pathogenic mutations detected in Foundation Medicine cohort of 1215 pediatric cancers. Table S2: Summary of RAS/MAPK pathway mutations and consequences detected in 48 RRD cancers.